Phinomics, a U.S.biotech company, has established its European hub at Bayer Co.Lab Berlin, focusing on extrachromosomal DNA (eccDNA) research to revolutionize cancer biology.The company's technology detects eccDNA, which plays a critical role in tumor evolution and drug resistance.

Unlike traditional genomic studies, Phinomics integrates multi-omics data with explainable AI models to uncover hidden disease mechanisms and therapeutic targets.EccDNA, small circular DNA molecules outside chromosomes, contributes to intratumoral heterogeneity and rapid adaptation to therapies.By analyzing these DNA rings, Phinomics aims to predict resistance pathways and improve precision oncology.

The Berlin location offers collaboration opportunities with institutions like Charité and the Max Delbrück Center, which are part of global cancer research initiatives.

This approach addresses gaps in current sequencing technologies and emphasizes the need for comprehensive biological data over computational power alone.